August 31, 2022

Medical device manufacturer Novo Nordisk, Inc. will pay $6.3 million to resolve claims that between 2012 and 2020 the company violated the False Claims Act by selling needles to the United States that were manufactured in non-designated countries in violation of the Trade Agreements Act.  USAO NJ

Tagged in: FCA Federal, Government Procurement Fraud, Healthcare Fraud, Medical Devices and DME, Trade Agreements,